Ultragenyx Pharmaceutical, Inc. (RARE)
22.51
-0.21
(-0.92%)
USD |
NASDAQ |
Feb 23, 16:00
22.54
+0.03
(+0.13%)
After-Hours: 19:59
Ultragenyx Pharmaceutical Research and Development Expense (Quarterly) : 194.22M for Dec. 31, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Corcept Therapeutics, Inc. | 68.85M |
| Johnson & Johnson | 4.268B |
| CorMedix, Inc. | 5.098M |
| Insmed, Inc. | 254.91M |
| Regeneron Pharmaceuticals, Inc. | 1.481B |